|
NOTE
10 – REVENUES
Disaggregation
of Net Revenues
The
Company’s net product revenues are summarized below:
| |
|
|
|
|
|
|
|
| |
|
Three
Months Ended
June 30, |
|
| |
|
2026 |
|
|
2025 |
|
| TONMYA |
|
$ |
10,954 |
|
|
$ |
— |
|
| Zembrace SymTouch |
|
|
1,996 |
|
|
|
1,570 |
|
| Tosymra |
|
|
594 |
|
|
|
428 |
|
| Total product
revenues |
|
$ |
13,544 |
|
|
$ |
1,998 |
|
|
|
|
|
|
|
|
|
|
| |
|
Six
Months Ended
June 30, |
|
| |
|
2026 |
|
|
2025 |
|
| TONMYA |
|
$ |
14,685 |
|
|
$ |
— |
|
| Zembrace SymTouch |
|
|
4,926 |
|
|
|
3,596 |
|
| Tosymra |
|
|
811 |
|
|
|
831 |
|
| Total product
revenues |
|
$ |
20,422 |
|
|
$ |
4,427 |
|
All
sales are generated in the United States.
Gross-to-Net
Sales Accruals
We
record gross-to-net sales accruals for chargebacks, rebates, sales and other discounts, and product returns, which are all customary
to the pharmaceutical industry.
An
analysis of the change in reserves for discounts and allowances is summarized as follows (in millions):
| |
|
|
|
|
|
|
|
|
| |
|
Accrued Liabilities |
|
Contra
Receivable |
|
|
| |
|
Rebates &
Discounts |
|
Returns |
|
Distribution &
Chargebacks |
|
Total |
| Reserve balance, January 1, 2026 |
|
5.7 |
|
2.2 |
|
1.0 |
$ |
8.9 |
| Current provisions relating to sales in current year |
|
13.0 |
|
1.0 |
|
4.4 |
$ |
18.4 |
| Payments/credits received in current year |
|
(8.2) |
|
(0.7) |
|
(2.9) |
$ |
(11.8) |
| Change in estimate related to sales in the prior year |
|
(2.8) |
|
0.1 |
|
(0.1) |
$ |
(2.8) |
| Reserve balance, June 30, 2026 |
$ |
7.7 |
$ |
2.6 |
$ |
2.4 |
$ |
12.7 |
| |
|
|
|
|
|
|
|
|
| |
|
Accrued Liabilities |
|
Contra
Receivable |
|
|
| |
|
Rebates &
Discounts |
|
Returns |
|
Distribution &
Chargebacks |
|
Total |
| Reserve balance, January 1, 2025 |
|
2.1 |
|
1.5 |
|
0.8 |
|
4.4 |
| Current provisions relating to sales in current year |
|
5.5 |
|
0.4 |
|
1.4 |
|
7.3 |
| Payments/credits received in current year |
|
(4.2) |
|
– |
|
(1.7) |
|
(5.9) |
| Reserve balance, June 30, 2025 |
$ |
3.4 |
$ |
1.9 |
$ |
0.5 |
$ |
5.8 |
|